Table 3.

UPDRS III–IV scores pre‐ and post‐LCIG therapy. The UPDRS‐IV off‐time/dyskinesia duration scale 1: 25% or less, 2: 25–50%, 3: 51–75%, 4: 76–100% of waking hours.

Patient	UPDRS‐III scores Pre‐LCIG ON‐stim (OFF‐meds)	UPDRS‐III scores pre‐LCIG ON‐ Stim (ON‐meds)*	UPDRS‐III scores post‐ LCIG ON‐Stim*	OFF‐time pre‐LCIGON‐Stim †	OFF‐time post‐LCIG ON‐Stim †	Sudden OFF pre‐LCIG ON meds ON‐Stim ‡	Sudden OFF post‐LCIG ON‐Stim ‡	Dyskinesia disability pre‐LCIG ON‐Stim ±	Dyskinesia disability post‐LCIG ON‐Stim ±	Dyskinesia duration pre‐LCIG ON‐Stim ±	Dyskinesia duration post‐LCIG ON‐Stim ±	Levodopa dose pre‐ LCIG (mg)**	Levodopa dose equivalent from LCIG (mg)**
1	42	28	33	3	0	Y	N	2	1	4	2	3150	3216
2	33	21	19	2	1	Y	N	2	1	3	1	2750	3000
3	38	28	16	3	1	Y	Y	0	1	1	2	2800	2600
4	N/A	28	31	3	1	Y	N	3	2	4	2	1800	1600
5	28	23	14	3	1	Y	Y	2	1	3	1	1100	1866
6	39	19	20	2	0	N	N	1	2	2	4	1850	1620

Median OFF meds ON‐stim pre‐LCIG UPDRS motor scores is 38. Median OFF meds pre‐DBS UPDRS motor score (Table 2) is 31. The UPDRS‐IV dyskinesia disability scale 0: Not disabling, 1: mildly disabling, 2: moderately disabling, 3: severely disabling, 4: completely disabled.

^*Median ON UPDRS motor scores pre (Median = 25.5/IQR = 21–28) and post (Median = 19.5/IQR = 15–31) LCIG therapy (P = 0.6) were not different. Wilcoxon signed rank test.

^†Median UPDRS‐IV OFF time pre (Median = 3) and post (Median = 1) LCIG therapy (ON‐Stim) were significantly different (P = 0.024). Wilcoxon signed rank test.

^‡3 of 5 patients with unpredictable fluctuations showed improvement after LCIG therapy.

^±UPDRS‐IV dyskinesia disability scores pre (Median = 2) and post (Median = 1) LCIG therapy (P = 0.4) and dyskinesia duration scores pre (Median = 3) and post (Median = 2) LCIG therapy (P = 0.2) were not significantly different. Wilcoxon signed rank test.

^**Median levodopa dose pre (Median = 2300 mg/IQR = 1625–2888 mg) and post (Median = 2233/IQR = 1615–3054 mg) LCIG therapy (P = 0.752). Wilcoxon signed rank test.